July 2026 Research Update

This month, the clearest message is that primary hyperoxaluria (PH) is being recognized sooner in some places, but the workup and care pathway still depend a lot on where someone is treated. A French dataset showed diagnosis delays shrinking since 2020, while a large international survey described ongoing gaps in access to certain tests and wide variation in treatment approaches in the siRNA era (RNA therapies that reduce oxalate production). [1] [2]

In France, time from first symptoms to genetic confirmation was much shorter in children than adults, and both groups had shorter delays than a prior 2015-2019 comparison group. The report described this as a halving of the diagnosis delay over 5 years, which fits with the idea that awareness and available therapies may be pushing earlier testing. [1]

Across 43 countries, clinicians answering a questionnaire reported that genetic testing was available in many centers, but plasma oxalate testing was often a bottleneck and some clinicians would not start genetic testing in certain chronic kidney disease situations. The same survey also showed that centers differ in how they use RNAi therapies (with lumasiran reported as more commonly used than nedosiran), dialysis strategies when kidney failure occurs, and whether to plan combined liver-kidney versus kidney-only transplant. [2]

For patients and caregivers, this month adds a practical picture of why PH experiences can differ across countries and even between centers. Earlier diagnosis in one region suggests progress is possible, but the survey shows that access to tests (especially plasma oxalate) and the way treatments are sequenced are still not consistent worldwide. This does not prove that any one approach is best, but it helps explain why families may hear different plans and why genetic confirmation and certain lab tests can be a key step in reaching a clear diagnosis. [1] [2]

What remains uncertain is how much shorter diagnosis delays or different care pathways change long-term outcomes in day-to-day practice, because these reports did not track outcomes in a way that can answer that question. Even so, they clarify that the biggest barriers are often system-level (test availability and local practice patterns), not only the disease itself. [2] [1]

A national pediatric registry report this month highlights that PH can already be advanced by the time it is diagnosed, with many children reaching kidney failure early. It also showed that outcomes varied by PH type and by whether transplantation occurred, with the report describing favorable long-term kidney outcomes after sequential liver-kidney transplantation and milder courses in PH2 and PH3. [3]

In 88 children with PH in Turkiye, about half had kidney failure at diagnosis and about half later started dialysis during follow-up. Mortality reached 27.7% during follow-up, particularly among children who already had kidney failure at diagnosis. [3]

The same registry described that sequential liver-kidney transplantation offered favorable long-term kidney outcomes, and it noted that PH2 and PH3 were milder with no mortality during follow-up. It also documented a genetic spectrum with recurring variants, reinforcing that PH is genetically diverse and that genetic confirmation was not available for every patient in routine care. [3]

For families, this registry puts numbers around something many people sense: in some children, PH is not discovered until significant kidney damage has already happened. The findings mainly matter for understanding prognosis and the potential seriousness of delayed recognition, rather than changing anything immediately for an individual patient. [3]

This report also helps clarify that PH type can relate to how the disease behaves over time, since PH2 and PH3 were described as having milder courses in this cohort. What remains uncertain is how closely these patterns match other countries and health systems, because this was one national registry and the summary does not describe all differences in care access across regions. [3]

Two very different reports this month point to ongoing unanswered questions beyond kidney stones and kidney function: how oxalate can affect other organs, and how to correctly identify those problems. A case report emphasized that skin lesions may be misread as calciphylaxis when they are actually cutaneous oxalosis, while a laboratory study suggested that IL-17A-driven inflammation could be part of the chain linking oxalate exposure to kidney and heart injury. [4] [5]

In one person with PH1 receiving lumasiran (an siRNA therapy), skin findings that were suspected to be calciphylaxis were repeatedly biopsied and ultimately identified as cutaneous oxalosis. The authors highlighted that careful tissue evaluation, including polarized light examination, was important to avoid the diagnostic pitfall. [4]

In a mouse model of oxalate nephropathy, researchers reported kidney injury alongside signs of broader inflammation and heart changes, and they measured higher IL-17A levels in both mice and a small group of people with PH. Blocking IL-17A in mice reduced kidney scarring and some inflammatory cell buildup and partially improved heart function, but the study also noted that not all problems resolved. [5]

For patients, these reports mainly add awareness that PH-related oxalate can show up outside the kidneys and may be hard to recognize at first. The skin case report is a reminder that appearance alone may not be enough to label a skin complication, because different conditions can look similar, and biopsy interpretation can matter for getting the name of the problem right. [4]

The IL-17A work is early research that may matter later if confirmed in people, because it proposes a specific inflammatory pathway that could be targeted in the future. What remains uncertain is how well the mouse findings predict outcomes in patients, since the human data in the summary were limited to measuring IL-17A in a small group and did not test an IL-17A-blocking treatment in people with PH. [5]